UroToday

Impact of Dose Holds and Reductions on Survival in the UNITE EV Cohort - Jeffrey Zhong

Jeffrey Zhong discusses a retrospective UNITE consortium analysis of dose modifications of enfortumab vedotin plus pembrolizumab in 360 patients with advanced urothelial carcinoma ...
UroToday

A ctDNA-Based Clinical-Genetic Prognostic Model for rPFS in mCRPC - Susan Halabi

Susan Halabi presents a ctDNA-based prognostic model for radiographic progression-free survival in mCRPC patients receiving first-line androgen receptor pathway inhibitors. The mo ...
UroToday

Managing Low-Volume Metachronous Metastatic Hormone-Sensitive Prostate Cancer - Pedro Barata

Pedro Barata discusses systemic therapy selection and monitoring in low-volume metachronous metastatic hormone-sensitive prostate cancer. He emphasizes that low disease volume doe ...
UroToday

ESMO 2024: DLL-3 Targeted Therapy for Neuroendocrine Prostate Cancer

(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13 th and 16 th, 2024 was host to a session on future therapy targets ...
UroToday

Phase II Neoadjuvant Study of SHR-A2102 plus Adebrelimab Before Radical Cystectomy - Yijun Shen

Yijun Shen discusses phase two results from a single-arm study of SHR-A2102 plus adebrelimab as neoadjuvant therapy in muscle-invasive bladder cancer. SHR-A2102 is a nectin-4 antibody-drug conjugate ...
UroToday

Duravelo-2 Interim Analysis of Zelenectide Peptide in Metastatic Urothelial Carcinoma - Daniel Petrylak

Daniel Petrylak shares interim results from Duravelo-2, a study of zelenectide in patients with one prior line of therapy for metastatic urothelial carcinoma. Zelenectide is a bicyclic peptide ...
UroToday

Safety and Efficacy of Synchronous Durvalumab with Hypofractionated Radiotherapy from the RAD-IO Study - Nicholas James

Nicholas James reviews data from a single-arm study of durvalumab added to a 5FU/mitomycin chemo-RT regimen as an alternative to cystectomy. The study was originally designed as a randomized trial but ...
UroToday

GUNS Trial Examines Biomarker‑Selected Neoadjuvant Approaches in High‑Risk Prostate Cancer - Martin Gleave

Matthew Cooperberg speaks with Martin Gleave about GUNS, a neoadjuvant adaptive umbrella trial for men with high-volume, high-grade prostate cancer. Now at 280 patients enrolled, GUNS sequences needle ...
UroToday

Enzalutamide in biochemically recurrent prostate cancer: clinical implications from EMBARK for real-world practice.

The fourth episode in this podcast series features a discussion between the two principal investigators from the phase III EMBARK trial (NCT02319837). EMBARK showed that in patients with prostate ...
UroToday

Newly diagnosed high-risk localized prostate cancer after multiple [177Lu]Lu-PSMA radioligand therapy in the context of metastatic parotid carcinoma: a case report.

Prostate-specific membrane antigen-direct radioligand therapy (PSMA RLT) is primarily used to treat castration-resistant metastatic prostate cancer (PCa) after prior treatment options have been ...
UroToday

Ultrasensitive ctDNA Detection in Advanced Renal Cell Carcinoma - Juan Ruiz-Bañobre

Juan Ruiz-Bañobre presents an ultrasensitive ctDNA analysis in advanced clear cell RCC, using a tumor-informed whole genome sequencing assay on serial plasma samples from 37 treatment-naive patients ...